ClinicalTrials.gov
public full text
Public Domain
CM-101 in PSC Patients -The SPRING Study
This study is designed to assess the safety, tolerability and activity of the anti-human CCL24 monoclonal antibody CM-101 in adult subjects with Primary Sclerosing Cholangitis (PSC). At least 68 subjects at approximately 50 sites will be randomized to receive either CM-101 at doses of 10 mg/kg or 20 mg/kg or matching placebo.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)#1338757
- Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases#1047840
- A Basket Study of CTA313 in Participants With Active Autoimmune Diseases#913763
- Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy#1228606
- Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC#870010
Record · ID 1394511
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive